Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: There was no discussion of costs. The story included quantitive information about weight loss over time. It did not quantify the impact on blood pressure. The story mentioned specific side effects of this particular medication combination. To be most informative to readers, the story should have mentioned that the potential for long-term harm is not known. And the rate at which people stopped taking the drug due to side effects should have been included. While indicating that several studies had been conducted in more than 4,500 people with various characteristics, the story never mentioned whether the studies are considered definitive or not; it also did not mention that the results of these studies have not yet been published in peer-reviewed journals. And while reporting that weight loss appeared to be dose dependent, there was no discussion of how weight loss compared with those in control groups. Lastly as the focus of the story appeared to be on an effect on blood pressure, it would seem that the story should have included some detail about the magnitude of the change. The story did not engage in overt disease mongering. The story mention that the study author and Dr. Aronne received funding from the manufacturer of this drug. It also included a quote from the president of the American Society of Hypertension who does not appear to have a financial tie to this product. There was no information about how well this product works in comparison with other approaches to weight loss. It's pretty clear from the story that the combination of the two drugs is not yet available. The story reported that the drug was a combination of two commercially available medications. It does not appear that the story relied solely or largely on a news release. Claim: Weight Loss Pill Also Lowers Blood Pressure
Although highlighting the effect of this product on blood pressure, the story did not explain how much blood pressure dropped. The story also didn't say how common the side effects are or how often people have to discontinue the medication due to side effects. It would have been helpful to remind readers of the possible pitfalls that may be ahead and that little is known about the long term use of this product in terms of both weight loss and potential risks that might result. Obesity and high blood pressure are very common conditions. There are few treatment for obesity that have been demonstrated to be enable people to lose weight and maintain that loss.

Paragraph: Democrats on a subcommittee of the House of Representatives Committee on Oversight and Reform released a cache of internal Juul emails and other documents that committee staff described as early attempts to "enter schools and convey its messaging directly to teenage children." Juul's use of social media influencers to promote its vaping devices in the years after it launched in 2015 also came under scrutiny. James Monsees, Juul's co-founder and chief product officer, told the committee that the company's target audience from the beginning has been adult cigarette smokers. Among efforts cited in the Juul documents released were a $134,000 payment to set up a five-week "holistic health education" summer camp at a Maryland charter school, recruiting children from third through 12th grades, and offering $10,000 to schools using the company's "youth prevention and education" programs for students, including those caught using e-cigarette products. "You don't think that sounds strange at all?" Representative Katie Hill, a Democrat, asked Juul's chief administrative officer, Ashley Gould. "All of these educational efforts were intended to keep youth from using the product," Gould responded. When Juul realized how the school involvement could be perceived as negative, "we stopped the program," she said. In a statement after the hearing, Juul said the $134,000 donation was to "facilitate already-existing community outreach and youth-prevention programs," and said the company "did not have any direct interaction with the students." Several committee members said Juul's initiatives appeared similar to past efforts by the tobacco industry to reach young people under the guise of smoking prevention programs. Gould said Juul, which is 35 percent owned by Marlboro maker Altria Group Inc (MO.N), halted its program last year once it became aware of the tobacco industry's past moves. Caleb Mintz, 17, a New York city high school student, testified at a separate hearing on Wednesday that a Juul representative came to his school as part of an educational program on mental health and addiction last year. He said in an interview Thursday that students received "mixed messages" about the product, being told it was safe but not to buy it. Mintz said after the hearing that the Juul presentation seemed to be "playing to the side of teens as rebellious. When a teen is told not to do something, they're more likely to do it." Members of the committee also quizzed Gould and Monsees over the use of social media influencers to promote Juul's vaping devices. Company executives early on agreed that "younger consumers age 25 to 34 was going to be the target of our initial campaign," Monsees said. "They would be more receptive to new technology solutions," such as the Juul device. Amid an enormous uptick in teenage use of e-cigarettes in 2018 a 78% increase among high school students from 2017 to 2018, according to federal data Juul said it ended all social media advertising last fall. Juul also pulled many flavored nicotine pods, except mint, menthol and tobacco, from retail stores, which Monsees said represented more than half of the company's sales at that time. Claim: U.S. lawmakers grill e-cigarette maker Juul over efforts targeted at schoolchildren.
E-cigarette maker Juul Labs Inc funded a "holistic health education" camp as part of efforts to market directly to school-aged children, members of a U.S. congressional panel said on Thursday, citing internal company documents.

Paragraph: J&J's view on naming of biosimilars contrasts that of Mylan Inc and Novartis AG over the past few months, as the U.S. Food and Drug Administration continues to work on drafting regulations for the approval of biosimilars cheaper versions of expensive biologics, or the original reference drugs. "Assigning names that are similar but not the same will appropriately reflect the legal and scientific reality that biosimilars are similar to but not the same as their reference products or other biosimilars," J&J's Chief Biotechnology Officer Jay Siegel said in a statement. Creating copies of biologics is complicated as these products are produced in living cells, bringing inevitable unpredictability. As a result, their copies can only ever be "similar," not exact replicas. Names of biosimilars are also bound to impact their sales and adoption as substitutes to the original products. Novartis and Mylan have both previously expressed support for a system that requires that a biosimilar share the same international non-proprietary name (INN) as the biologic products to which it refers, saying that same names would avoid frivolous brand tactics and confusion in the marketplace. Mylan in September said it supported a petition filed by the Washington, DC-based Generic Pharmaceutical Association that recommended biosimilars have the same names because by definition they are highly similar to their reference products and have no meaningful differences that require a unique name. Novartis advocated for the same by filing its own petition in October. Biologic medicines, typically administered via an injection, and are used to treat cancers, immunological diseases like rheumatoid arthritis and multiple sclerosis and other chronic illnesses, but their high price tag can keep them out of reach for many patients. The FDA in February 2012 issued draft guidance on approval pathways for biosimilars, but is yet to finalize that guidance, while European regulators have already cleared cheaper copies of some biotech medicines. The global biosimilars market is expected to be worth about $11 billion to $25 billion in 2020, equivalent to a modest 4 to 10 percent of total biotech drug sales by that time, according to healthcare information firm IMS Health. Claim: J&J petitions FDA to require 'similar' names for biosimilars, biologics.
Johnson & Johnson on Wednesday said it submitted a citizen petition asking that U.S. health regulators require copies of biological products to bear names that are similar and not identical to those of their reference products.